Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif

Nucleic Acids Research

Volumn 39, Issue 6, 2011, Pages 2404-2415

  Bernacchi, Serena ^a   Mercenne, Gaëlle ^a   Tournaire, Clémence ^a   Marquet, Roland ^a   Paillart, Jean Christophe ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HIV 1 VIRAL INFECTIVITY FACTOR; MUTANT PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LIGHT SCATTERING; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROLINE RICH PROTEIN DOMAIN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MULTIMERIZATION; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE;

AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; FLUORESCENCE; HIV-1; MUTATION; PROLINE; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RNA, VIRAL; RNA-BINDING PROTEINS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79953686217     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkq979     Document Type: Article

References (86)

1. Malim,M.H. and Emerman,M. (2008) HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe., 3, 388-398. (Pubitemid 351784365)
2. Sodroski,J., Goh,W.C., Rosen,C., Tartar,A., Portetelle,D., Burny,A. and Haseltine,W. (1986) Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science, 231, 1549-1553.
3. Gabuzda,D.H., Lawrence,K., Langhoff,E., Terwilliger,E., Dorfman,T., Haseltine,W.A. and Sodroski,J. (1992) Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol., 66, 6489-6495.
4. Borman,A.M., Quillent,C., Charneau,P., Dauguet,C. and Clavel,F. (1995) Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J. Virol., 69, 2058-2067.
5. Courcoul,M., Patience,C., Rey,F., Blanc,D., Harmache,A., Sire,J., Vigne,R. and Spire,B. (1995) Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J. Virol., 69, 2068-2074.
6. Henriet,S., Mercenne,G., Bernacchi,S., Paillart,J.C. and Marquet,R. (2009) Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol. Mol. Biol. Rev., 73, 211-232.
7. Wissing,S., Galloway,N.L. and Greene,W.C. (2010) HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol. Aspects Med, in press.
8. Sheehy,A.M., Gaddis,N.C. and Malim,M.H. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med., 9, 1404-1407.
9. Wiegand,H.L., Doehle,B.P., Bogerd,H.P. and Cullen,B.R. (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J., 23, 2451-2458. (Pubitemid 38954852)
10. Mariani,R., Chen,D., Schrofelbauer,B., Navarro,F., Konig,R., Bollman,B., Munk,C., Nymark-McMahon,H. and Landau,N.R. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell, 114, 21-31. (Pubitemid 36859838)
11. Yu,X., Yu,Y., Liu,B., Luo,K., Kong,W., Mao,P. and Yu,X.F. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science, 302, 1056-1060.
12. Holmes,R.K., Malim,M.H. and Bishop,K.N. (2007) APOBEC-mediated viral restriction: not simply editing? Trends. Biochem. Sci., 32, 118-128.
13. Hultquist,J.F. and Harris,R.S. (2009) Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol., 4, 605.
14. Yang,B., Chen,K., Zhang,C., Huang,S. and Zhang,H. (2007) Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem., 282, 11667-11675.
15. Luo,K., Wang,T., Liu,B., Tian,C., Xiao,Z., Kappes,J. and Yu,X.F. (2007) Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol., 81, 7238-7248.
16. Chiu,Y.L. and Greene,W.C. (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol., 26, 317-353.
17. Marin,M., Rose,K.M., Kozak,S.L. and Kabat,D. (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med., 9, 1398-1403.
18. Mehle,A., Goncalves,J., Santa-Marta,M., McPike,M. and Gabuzda,D. (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev., 18, 2861-2866. (Pubitemid 39602304)
19. Conticello,S.G., Langlois,M.A., Yang,Z. and Neuberger,M.S. (2007) DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv. Immunol., 94, 37-73.
20. Liu,B., Sarkis,P.T., Luo,K., Yu,Y. and Yu,X.F. (2005) Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol., 79, 9579-9587.
21. Iwatani,Y., Chan,D.S., Liu,L., Yoshii,H., Shibata,J., Yamamoto,N., Levin,J.G., Gronenborn,A.M. and Sugiura,W. (2009) HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc. Natl. Acad. Sci. USA, 106, 19539-19544.
22. Opi,S., Kao,S., Goila-Gaur,R., Khan,M.A., Miyagi,E., Takeuchi,H. and Strebel,K. (2007) Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol., 81, 8236-8246. (Pubitemid 47101509)
23. Goila-Gaur,R., Khan,M.A., Miyagi,E. and Strebel,K. (2009) Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif. J. Virol., 83, 1156-1160.
24. Stopak,K., de Noronha,C., Yonemoto,W. and Greene,W.C. (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell, 12, 591-601.
25. Kao,S., Khan,M.A., Miyagi,E., Plishka,R., Buckler-White,A. and Strebel,K. (2003) The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol., 77, 11398-11407. (Pubitemid 37271638)
26. Mercenne,G., Bernacchi,S., Richer,D., Bec,G., Henriet,S., Paillart,J.C. and Marquet,R. (2010) HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res., 38, 633-646.
27. Tian,C., Yu,X., Zhang,W., Wang,T., Xu,R. and Yu,X.F. (2006) Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol., 80, 3112-3115.
28. Simon,V., Zennou,V., Murray,D., Huang,Y., Ho,D.D. and Bieniasz,P.D. (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog, 1, e6.
29. Dang,Y., Davis,R.W., York,I.A. and Zheng,Y.H. (2010) Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol., 84, 5741-5750.
30. Chen,G., He,Z., Wang,T., Xu,R. and Yu,X.F. (2009) A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol., 83, 8674-8682.
31. Dang,Y., Wang,X., Zhou,T., York,I.A. and Zheng,Y.H. (2009) Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol., 83, 8544-8552.
32. Lee,T.H., Coligan,J.E., Allan,J.S., McLane,M.F., Groopman,J.E. and Essex,M. (1986) A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science, 231, 1546-1549.
33. Henriet,S., Sinck,L., Bec,G., Gorelick,R.J., Marquet,R. and Paillart,J.C. (2007) Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res., 35, 5141-5153. (Pubitemid 47394198)
34. Henriet,S., Richer,D., Bernacchi,S., Decroly,E., Vigne,R., Ehresmann,B., Ehresmann,C., Paillart,J.C. and Marquet,R. (2005) Cooperative and specific binding of Vif to the 5′ region of HIV-1 genomic RNA. J. Mol. Biol., 354, 55-72.
35. Bernacchi,S., Henriet,S., Dumas,P., Paillart,J.C. and Marquet,R. (2007) RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study. J. Biol. Chem., 282, 26361-26368.
36. Dettenhofer,M., Cen,S., Carlson,B.A., Kleiman,L. and Yu,X.F. (2000) Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J. Virol., 74, 8938-8945.
37. Zhang,H., Pomerantz,R.J., Dornadula,G. and Sun,Y. (2000) Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J. Virol., 74, 8252-8261. (Pubitemid 30666673)
38. Oberste,M.S. and Gonda,M.A. (1992) Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes, 6, 95-102.
39. Yu,Y., Xiao,Z., Ehrlich,E.S., Yu,X. and Yu,X.F. (2004) Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev., 18, 2867-2872.
40. Schmitt,K., Hill,M.S., Ruiz,A., Culley,N., Pinson,D.M., Wong,S.W. and Stephens,E.B. (2009) Mutations in the highly conserved SLQYLA motif of Vif in a simian-human immunodeficiency virus result in a less pathogenic virus and are associated with G-to-A mutations in the viral genome. Virology, 383, 362-372.
41. Xiao,Z., Ehrlich,E., Yu,Y., Luo,K., Wang,T., Tian,C. and Yu,X.F. (2006) Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology, 349, 290-299.
42. Mehle,A., Thomas,E.R., Rajendran,K.S. and Gabuzda,D. (2006) A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem., 281, 17259-17265.
43. Barraud,P., Paillart,J.C., Marquet,R. and Tisne,C. (2008) Advances in the structural understanding of Vif proteins. Curr. HIV Res., 6, 91-99.
44. Yang,S., Sun,Y. and Zhang,H. (2001) The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J. Biol. Chem., 276, 4889-4893.
45. Yang,B., Gao,L., Li,L., Lu,Z., Fan,X., Patel,C.A., Pomerantz,R.J., DuBois,G.C. and Zhang,H. (2003) Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem., 278, 6596-6602.
46. Auclair,J.R., Green,K.M., Shandilya,S., Evans,J.E., Somasundaran,M. and Schiffer,C.A. (2007) Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins, 69, 270-284. (Pubitemid 47429290)
47. Simon,J.H., Fouchier,R.A., Southerling,T.E., Guerra,C.B., Grant,C.K. and Malim,M.H. (1997) The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J. Virol., 71, 5259-5267. (Pubitemid 27258199)
48. Miller,J.H., Presnyak,V. and Smith,H.C. (2007) The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology, 4, 81.
49. Donahue,J.P., Vetter,M.L., Mukhtar,N.A. and D'Aquila,R.T. (2008) The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology, 377, 49-53.
50. Kataropoulou,A., Bovolenta,C., Belfiore,A., Trabatti,S., Garbelli,A., Porcellini,S., Lupo,R. and Maga,G. (2009) Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res., 37, 3660-3669.
51. Bergeron,J.R., Huthoff,H., Veselkov,D.A., Beavil,R.L., Simpson,P.J., Matthews,S.J., Malim,M.H. and Sanderson,M.R. (2010) The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog, 6, e1000925.
52. Wolfe,L.S., Stanley,B.J., Liu,C., Eliason,W.K. and Xiong,Y. (2010) Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. J. Virol., 84, 7135-7139.
53. Goncalves,J., Shi,B., Yang,X. and Gabuzda,D. (1995) Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J. Virol., 69, 7196-7204.
54. Bouyac,M., Courcoul,M., Bertoia,G., Baudat,Y., Gabuzda,D., Blanc,D., Chazal,N., Boulanger,P., Sire,J., Vigne,R. et al. (1997) Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J. Virol., 71, 9358-9365. (Pubitemid 27492378)
55. Khan,M.A., Aberham,C., Kao,S., Akari,H., Gorelick,R., Bour,S. and Strebel,K. (2001) Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J. Virol., 75, 7252-7265. (Pubitemid 32743158)
56. Bardy,M., Gay,B., Pebernard,S., Chazal,N., Courcoul,M., Vigne,R., Decroly,E. and Boulanger,P. (2001) Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. J. Gen. Virol., 82, 2719-2733.
57. Simon,J.H. and Malim,M.H. (1996) The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J. Virol., 70, 5297-5305. (Pubitemid 26240703)
58. Dettenhofer,M. and Yu,X.F. (2001) Characterization of the biosynthesis of human immunodeficiency virus type 1 Env from infected T-cells and the effects of glucose trimming of Env on virion infectivity. J. Biol. Chem., 276, 5985-5991.
59. Simon,J.H., Carpenter,E.A., Fouchier,R.A. and Malim,M.H. (1999) Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J. Virol., 73, 2667-2674. (Pubitemid 29135651)
60. Stanley,B.J., Ehrlich,E.S., Short,L., Yu,Y., Xiao,Z., Yu,X.F. and Xiong,Y. (2008) Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol., 82, 8656-8663.
61. Balaji,S., Kalpana,R. and Shapshak,P. (2006) Paradigm development: comparative and predictive 3D modeling of HIV-1 virion infectivity factor (Vif). Bioinformation, 1, 290-309.
62. Lv,W., Liu,Z., Jin,H., Yu,X. and Zhang,L. (2007) Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. Org. Biomol. Chem., 5, 617-626.
63. Paul,I., Cui,J. and Maynard,E.L. (2006) Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc. Natl Acad. Sci. USA, 103, 18475-18480.
64. Giri,K. and Maynard,E.L. (2009) Conformational analysis of a peptide approximating the HCCH motif in HIV-1 Vif. Biopolymers, 92, 417-425.
65. Reingewertz,T.H., Benyamini,H., Lebendiker,M., Shalev,D.E. and Friedler,A. (2009) The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state. Protein Eng. Des. Sel., 22, 281-287.
66. Scatchard,G. (1949) The attraction of proteins for small ions and molecules. Ann. N Y Acad. Sci., 51, 660-672.
67. McGhee,J.D. and von Hippel,P.H. (1974) Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. J. Mol. Biol., 86, 469-489.
68. Tsodikov,O.V., Holbrook,J.A., Shkel,I.A. and Record,M.T. Jr (2001) Analytic binding isotherms describing competitive interactions of a protein ligand with specific and nonspecific sites on the same DNA oligomer. Biophys. J., 81, 1960-1969.
69. Chen,Y. and Barkley,M.D. (1998) Toward understanding tryptophan fluorescence in proteins. Biochemistry, 37, 9976-9982. (Pubitemid 28366351)
70. Lakowicz,J.R. (1999) In Lakowicz,J.R. (ed.), Principles of Fluorescence Spectroscopy, 2nd edn. Plenum Press, NY.
71. Baudin,F., Marquet,R., Isel,C., Darlix,J.L., Ehresmann,B. and Ehresmann,C. (1993) Functional sites in the 5′ region of human immunodeficiency virus type 1 RNA form defined structural domains. J. Mol. Biol., 229, 382-397.
72. Reingewertz,T.H., Shalev,D.E. and Friedler,A. (2010) Structural disorder in the HIV-1 Vif protein and interaction-dependent gain of structure. Protein Pept. Lett., 17, 988-998.
73. Fink,A.L. (2005) Natively unfolded proteins. Curr. Opin. Struct. Biol., 15, 35-41.
74. Wright,P.E. and Dyson,H.J. (1999) Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol., 293, 321-331.
75. Dyson,H.J. and Wright,P.E. (2004) Unfolded proteins and protein folding studied by NMR. Chem. Rev., 104, 3607-3622.
76. Ohagen,A. and Gabuzda,D. (2000) Role of Vif in stability of the human immunodeficiency virus type 1 core. J. Virol., 74, 11055-11066. (Pubitemid 32223970)
77. Stoylov,S.P., Vuilleumier,C., Stoylova,E., De Rocquigny,H., Roques,B.P., Gerard,D. and Mely,Y. (1997) Ordered aggregation of ribonucleic acids by the human immunodeficiency virus type 1 nucleocapsid protein. Biopolymers, 41, 301-312.
78. Gallois-Montbrun,S., Kramer,B., Swanson,C.M., Byers,H., Lynham,S., Ward,M. and Malim,M.H. (2007) Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol., 81, 2165-2178.
79. Kozak,S.L., Marin,M., Rose,K.M., Bystrom,C. and Kabat,D. (2006) The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem., 281, 29105-29119.
80. Wichroski,M.J., Robb,G.B. and Rana,T.M. (2006) Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog, 2, e41.
81. Chiu,Y.L., Soros,V.B., Kreisberg,J.F., Stopak,K., Yonemoto,W. and Greene,W.C. (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+T cells. Nature, 435, 108-114. (Pubitemid 40655917)
82. Chiu,Y.L. and Greene,W.C. (2006) Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol., 27, 291-297.
83. Goila-Gaur,R., Khan,M.A., Miyagi,E., Kao,S., Opi,S., Takeuchi,H. and Strebel,K. (2008) HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology, 372, 136-146. (Pubitemid 351215461)
84. Soros,V.B. and Greene,W.C. (2007) APOBEC3G and HIV-1: strike and counterstrike. Curr. HIV/AIDS Rep., 4, 3-9.
85. Conticello,S.G., Harris,R.S. and Neuberger,M.S. (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol., 13, 2009-2013.
86. Walker,R.C. Jr, Khan,M.A., Kao,S., Goila-Gaur,R., Miyagi,E. and Strebel,K. (2010) Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif. J. Virol., 84, 5201-5211.